

AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims

1. (currently amended): A method of treating multiple sclerosis (MS), comprising administering to an individual pharmaceutically-effective amounts of cpn10 and IFN- β , wherein the amounts of cpn10 and IFN- β are suboptimal when administered alone and wherein the therapeutic effect of administering cpn10 and IFN- β is greater than that of administering an equivalent the suboptimal amount of cpn10 or IFN- β alone.
2. (original): The method of claim 1, when used as a treatment to prevent relapse of MS.
3. (previously presented): The method of claim 1, wherein IFN- β and cpn10 are administered together.
4. (previously presented): The method of claim 1, wherein IFN- β and cpn10 are administered separately.
5. (original): The method of claim 3, wherein IFN- β and cpn10 are administered by injection.
6. (original): The method of claim 4, wherein cpn10 is administered orally.
7. (previously presented): The method of claim 4, wherein IFN- β is administered by injection.

8. (previously presented): The method of claim 1, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 5-60 mg of cpn10.

9. (original): The method of claim 8, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 10-30 mg of cpn10.

10. (previously presented): The method of claim 1, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 1-10 Million International Units (MIU) of IFN- β .

11. (previously presented): The method of claim 10, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 4-6 MIU of IFN- β .

12. (withdrawn): A pharmaceutical composition for treating MS, wherein said composition an amount of cpn10 and of IFN- β effective to treat MS in combination with a pharmaceutically-acceptable carrier or diluent.

13. (withdrawn): The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 5-60 mg of cpn10.

14. (withdrawn): The composition of claim 13, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 10-30 mg of cpn10.

15. (withdrawn): The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 1-10 MIU of IFN- β .

16. (withdrawn): The composition of claim 15, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 4-6 MIU of IFN- β .

17. (withdrawn): A kit comprising an amount of cpn10 and IFN- β effective to treat MS and, in a separate container, a pharmaceutically-acceptable carrier or diluent.

18. (withdrawn): The kit of claim 17, wherein said IFN- β is in dehydrated form, which in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

19. (withdrawn): The kit of claim 18, wherein said cpn10 is in dehydrated form and in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

20. (withdrawn): The kit of claim 17, wherein said cpn10 is in tablet or capsule form.

21. (withdrawn): The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 5-60 mg of cpn10.

22. (withdrawn): The kit of claim 21, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 10-30 mg of cpn10.

23. (withdrawn): The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 1-10 MIU of IFN- β .

24. (withdrawn): The kit of claim 23, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 4-6 MIU of IFN- β .

25. (new): A method of treating multiple sclerosis (MS), comprising administering to an individual pharmaceutically-effective amounts of cpn10 and IFN- β wherein the therapeutic effect of administering cpn10 and IFN- β is greater than that of administering an equivalent amount of cpn10 or IFN- β alone with respect to delaying relapse of MS.